Treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma in the US

• Published in: JAMA network open Vol. 7; no. 5; p. e249417
• Main Authors: Mathew Thomas, Vinay, Jo, Yeonjung, Tripathi, Nishita, Roy, Soumyajit, Chigarira, Beverly, Narang, Arshit, Gebrael, Georges, Hage Chehade, Chadi, Sayegh, Nicolas, Galarza Fortuna, Gliceida, Ji, Richard, Campbell, Patrick, Li, Haoran, Agarwal, Neeraj, Gupta, Sumati, Swami, Umang
• Format: Journal Article
• Language: English
• Published: United States 01.05.2024
• Subjects: Aged; Aged, 80 and over; Antibodies, Monoclonal - therapeutic use; Antineoplastic Agents - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Carboplatin - therapeutic use; Carcinoma, Transitional Cell - drug therapy; Cisplatin - therapeutic use; Female; Humans; Immune Checkpoint Inhibitors - therapeutic use; Male; Middle Aged; Retrospective Studies; United States; Urinary Bladder Neoplasms - drug therapy; Urinary Bladder Neoplasms - pathology; Urologic Neoplasms - drug therapy; Urologic Neoplasms - pathology; United States

The treatment paradigm for advanced urothelial carcinoma (aUC) has undergone substantial transformation due to the introduction of effective, novel therapeutic agents. However, outcomes remain poor, and little is known about current treatment approaches and attrition rates for patients with aUC. To...